🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

If it’s nighttime where you are, and you’re relatively more north, I recommend going outside and looking up right now. Thanks, Nature! #Auroraborealis

Fantastic effort in collaboration with my colleagues Katrina Pedersen, MD, MS Yin Cao WillChapmanJr MichaelIglesia Siteman Cancer Center. Abdominal pain is the most common symptom. GI bleeding most strongly associated with diagnosis. Check your 💩. Get your screening colonoscopy.

😳 nytimes.com/live/2024/12/0…

We are electric! Always awesome yet far too rare for mOS benefit in Ph3 PDAC trial, but PANOVA-3 mOS 16.2m for TTF+GnP vs 14.2m GnP?🤔 Look forward to seeing full data and actual pt experience with device to determine clin significance. biospace.com/press-releases…

Congratulations to uber-talented WashU Medicine Hematology-Oncology Fellowship #jerodsears on a great poster presentation at ASCO #GI25 #SmallBowelAdenocarcinomaResearch 🥳🥳🥳

We prefer fair and balanced clocks. Daylight Saving Time is a mandate to wake early and sleep less. Permanent Standard Time keeps the sun’s zenith at noon—best for health and safety!

Prior Auth Grievance Log: BCBS BCBS - FEP 2 hrs my time + hrs other teammates wasted + MOST IMPORTANTLY 4 weeks treatment delay for prior auth of Panitumumab+FOLFIRI in stg4 RAS/RAF Wild type L-sided colon cancer pt. This is the definition of on-label treatment. #EndPriorAuth

Getting excited for #ASCO25, especially to see *ATOMIC* data during Plenary session (LBA1)! Cautiously optimistic that this means our stage III dMMR patients will benefit 🙌 Congrats to Frank Sinicrope, MD #Alliance 🥳 meetings.asco.org/abstracts-pres…

Get key takeaways from the ASCO Annual Meeting in our 2-day high-impact, expert-led and curated learning experience, Best of ASCO Minneapolis. Register TODAY for our best rates. #ASCO25

BREAKWATER shows that 1L EC+FOLFOX results in mPFS 12.8m and mOS 30.3m!! 🥹🥲 That mOS far exceeded my greatest hope for this study. A great turning point for a bad actor 🙌👊🏻 #ASCO25

Come to this— Christine Parseghian, MD and I will make this year’s pivotal GI data interesting for you. And MSP in July is not to be missed. #BestofASCO25

🥳 Adjuvant FOLFOX/Atezo vs FOLFOX for resected dMMR stage 3 colon cancer more positive than I expected—DFS 3 yr 0.50 ! My opinion of trial we need now: randomized neoadj ICI vs adj ICI +|- chemo vs periop ICI Excellent presentations Frank Sinicrope, MD Myriam Chalabi 🤩

Another year with a great ASCO plenary viewing group! Love your insights #richardwilson Madison Conces, MD Smitha Krishnamurthi Kristen Ciombor #staceycohen Aparna Raj Parikh #christinawu

CRC staging: AJCC v9 Era Past: “TNM.” Now: “TNDM” staging system, incorporating tumor deposits as independent entity. I like it. Better than N1c grouping-better reflects survival risk. Will be a learning curve though… AJCC v10 prediction: TNDM+ctDNA 🤔

Yankee Hotel Foxtrot…was released 24(!) years ago and is still the only thing I think of whenever I’m by the Chicago River for some reason… 🤔😬 #ASCO25

As another Annual Meeting winds down, I’m reminded of what the ASCO acronym actually stands for: Academic Summer Camp for Oncologists Bet you didn’t know that 😂👍 Some fantastic data, heated debates, and thought provoking convos for GI cancers this #ASCO25 See you all soon

Want a quick update in medical oncology on July 19 (with some heme updates in the mix)...? If so, we have the course for you! I can promise excellent content/speakers and there is a livestream (virtual) option too for those who cannot attend in person. ce.mayo.edu/hematology-and…

🧬Spoiler alert: it’s important. Really important. And becomes more so this past year. #breakwater #checkmate8hw How/when do you test? 🤔 Thanks OncLive.com John Marshall for giving an excuse to chat and learn from each other 🙏

Panelists John Marshall, Dr. Marwan G. Fakih, Arvind Dasari, MD, MS, and Katrina Pedersen, MD, MS discuss how doublet immunotherapy with ipilimumab and nivolumab provides superior outcomes compared to single-agent PD-1 therapy or chemotherapy in microsatellite instability-high colorectal cancer, supporting the

Panelists John Marshall, Dr. Marwan G. Fakih, Arvind Dasari, MD, MS, and Katrina Pedersen, MD, MS discuss the role of ctDNA in the Management of mCRC. onclive.com/view/the-role-… via @onclive